Categories
Health

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn is actually  a   biotech that has been effective vigilantly but unsuccessfully to produce an one-time therapy, variously called Pro 140, leronlimab, as well as Vyrologix.

In development of this particular treatment, CytoDyn has cast its net wide and far both geographically and in terms of possible indications.

CytoDyn’s inventories of leronlimab are actually building up, whether they’ll ever be used is actually an open question.

While CYDY  happens to be dawdling, promote opportunities for leronlimab as being a combination treatment in the curing of multi-drug-resistant HIV happen to be closing.

I’m writing my fifteenth CytoDyn (OTCQB:CYDY) article on FintechZoom to celebrate the sale made of my past few shares. The first CytoDyn article of mine, “CytoDyn: What to be able to Do When It’s Too Good To Be True?”, set out all of the following prediction:

Instead I expect it to become a serial disappointer. CEO Pourhassan offered such a very marketing image in the Uptick Newswire employment interview which I came away with a poor opinion of the company.

Irony of irony, the poor impression of mine of the business enterprise has grown steadily, although the disappointment has not been financial. Two years ago CytoDyn was trading <$1.00. On 2/19/20 as I write, it trades during $5.26; my closing transaction was on 2/11/21 > $6.00.

What manner of stock  is this that gives a > 6 bagger yet still disappoints? Therein sits the story; permit me to explain.

CytoDyn acquired its much-storied treatment (which I shall relate to as leronlimab) returned during 2012, announced as follows:

CytoDyn Inc…. has completed the acquisition of Pro 140, an experimental humanized monoclonal antibody (MAB) targeting the CCR5 receptor of the therapy as well as avoidance of HIV, from Progenics Pharmaceuticals, Inc. of Tarrytown, NY. Pro 140 is a late Stage II clinical development mAb with demonstrated anti-viral activity of HIV infected subjects. Today’s transaction of $3.5 zillion transfers ownership of the expertise as well as linked intellectual property coming from Progenics to CytoDyn, as well as roughly 25 million mg of majority drug substance…. milestone payments upon commencement of a phase III clinical trial ($1.5 million) along with the first new drug application approval ($5 million), and even royalty payments of 5 percent of net sales after commercialization.

Since that moment, CytoDyn’s helping nous, Nader Pourhassan [NP] has transformed this inauspicious acquisition right into a springboard for CytoDyn to acquire a sector cap > $3.5 billion. It’s done so in exclusive reliance on leronlimab.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News
CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Rather than having a pipeline with many indications and numerous therapies, it has this individual therapy in addition to a “broad pipeline of indications” since it places it. I call some pipelines, “pipedots.” In CytoDyn’s situation it touts the leronlimab of its as a likely advantageous therapy in dozens of indications.

The opening banner of its on its website (below) shows an active company with diverse interests albeit focused on leronlimab, several disease sorts, multiple presentations and multiple publications.

Can it all be smoke cigarettes and mirrors? That is a question I’ve been asking myself from the very start of the interest of mine in this company. Judging with the multiples of a huge number of diverse responses on listings accessible via Seeking Alpha’s CytoDyn Summary webpage, I am much from alone in this particular question.

CytoDyn is a classic battleground, or possibly some could say cult stock. Its adherents are fiercely protective of the prospects of its, quick to label some bad opinions as scurrilous short mongering.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Leave a Reply

Your email address will not be published. Required fields are marked *